---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-090727"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:08:49.146310+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics Q2 2024 net loss widens to $126.4M; CASGEVY launch with 35+ ATCs

## Summary
- Net loss $126.4M vs $77.7M in Q2 2023; R&D expenses down to $80.2M from $101.6M.
- Cash, equivalents and securities $2.01B as of June 30, up from $1.70B at Dec 31, 2023.
- CASGEVY: >35 ATCs activated globally; ~20 patients have had cells collected as of mid-July.
- CTX112 CD19 CAR T Phase 1/2 trial opened for SLE; preliminary oncology data expected this year.
- Appointed Naimish Patel as CMO; promoted Julianne Bruno to COO and Susan Kim to SVP IR.

## SEC filing metadata
- accession: 0000950170-24-090727
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017024090727/0000950170-24-090727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017024090727/crsp-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-090727
- JSON: https://secwatch.observer/filing/0000950170-24-090727.json
- Plain text: https://secwatch.observer/filing/0000950170-24-090727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.